Business Description
Celldex Therapeutics Inc
NAICS : 325413
SIC : 2835
ISIN : US15117B2025
Description
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 166.64 | |||||
| Equity-to-Asset | 0.92 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 36.65 | |||||
| Beneish M-Score | 0.29 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -17.2 | |||||
| 3-Year EBITDA Growth Rate | -23.1 | |||||
| 3-Year EPS without NRI Growth Rate | -21.3 | |||||
| 3-Year FCF Growth Rate | -16.7 | |||||
| 3-Year Book Growth Rate | 13.3 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 35.01 | |||||
| 9-Day RSI | 37.17 | |||||
| 14-Day RSI | 39.69 | |||||
| 6-1 Month Momentum % | 71.74 | |||||
| 12-1 Month Momentum % | 20.9 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 13.87 | |||||
| Quick Ratio | 13.87 | |||||
| Cash Ratio | 13.61 | |||||
| Days Sales Outstanding | 49.41 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -12.2 | |||||
| Shareholder Yield % | 0.02 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -2063.66 | |||||
| Net Margin % | -2054.76 | |||||
| FCF Margin % | -1585.2 | |||||
| ROE % | -44.69 | |||||
| ROA % | -41.05 | |||||
| ROIC % | -370.85 | |||||
| ROC (Joel Greenblatt) % | -1960.12 | |||||
| ROCE % | -44 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 270.23 | |||||
| PB Ratio | 4.82 | |||||
| Price-to-Tangible-Book | 5.15 | |||||
| EV-to-EBIT | -14.49 | |||||
| EV-to-Forward-EBIT | -11.08 | |||||
| EV-to-EBITDA | -14.81 | |||||
| EV-to-Forward-EBITDA | -11.08 | |||||
| EV-to-Revenue | 299.06 | |||||
| EV-to-Forward-Revenue | 395.85 | |||||
| EV-to-FCF | -18.87 | |||||
| Price-to-Median-PS-Value | 2.98 | |||||
| Price-to-Net-Current-Asset-Value | 5.24 | |||||
| Price-to-Net-Cash | 5.34 | |||||
| Earnings Yield (Greenblatt) % | -6.9 | |||||
| FCF Yield % | -4.49 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers